Efficacy screening

DefiniGEN's Phenotypic Screening Service helps you move quickly and efficiently from screening library to promising candidates by combining our expertise at generating iPSC-derived hepatocyte cellular models of disease with our wide panel of bespoke bioassays.

We work as partners with your team to design and implement in-house screening of small molecules, RNAi/oligonucleotide therapeutics, AAVs and virtually any modality so you can advance your program at speed.

SPB_4274-1
SPB_4274-1

Toxicology Screening

Discover DefiniGEN's game-changing platform for in vitro ADME and toxicology screening. Our proprietary Opti-Hep® iPSC-derived cells offer unparalleled accuracy and predictive power in hepatotoxicity testing, helping you to identify potential drug compounds against liver diseases.

Disease Modeling

DefiniGEN's iPSC-based OptiDIFF platform enables the creation of high-quality wild-type and disease-specific cell models, providing mature cells that accurately replicate various disease phenotypes. These models offer a powerful tool for screening or characterizing lead compounds in areas that were previously challenging to study. We also provide custom model development tailored to specific research needs, advancing drug discovery and therapeutic research.

SPB_4274-1